35 completed, 12 unknown, 10 terminated, 6 recruiting. 73 Phase 2, 14 Phase 1, 5 Phase 3.
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Recruiting | Oncolytics Biotech | 60 | 2026-04-30 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer Inavolisib, Bevacizumab, FOLFOX - Colorectal Cancer | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-02-01 | 2026-02-09 | |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer AK112, FOLFIRI, Bevacizumab - Colorectal Cancer, Ivonescimab | Phase 2 | Not yet recruiting | Sun Yat-sen University | 130 | 2025-08-10 | 2025-06-15 |
| Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy Niraparib, FOLFIRI, Ipilimumab - Pancreatic Adenocarcinoma Metastatic | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 68 | 2025-05-07 | 2026-10-13 |
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Onvansertib, FOLFIRI, Bevacizumab - Metastatic Colorectal Cancer, CRC | Phase 2 | Active not recruiting | Cardiff Oncology | 110 | 2024-02-27 | 2026-06-16 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| RP-6306 in Patients With Advanced Cancer RP-6306, Gemcitabine, FOLFIRI Protocol - Advanced Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 28 | 2023-05-24 | 2026-02-06 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With NEN PM8002, FOLFIRI - Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | Biotheus Inc. | 31 | 2023-05-17 | 2026-07-09 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Onvansertib, FOLFIRI, Bevacizumab - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Completed | Cardiff Oncology | 23 | 2023-03-17 | 2025-01-10 |
| A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer Ametumumab, Anti-PD-1 monoclonal antibody, Cetuximab - Colorectal Cancer | Phase 2 | Unknown | Shanghai Celfuture Biotech Co., Ltd. | 84 | 2023-01-01 | 2023-02-01 |
| The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer Fruquintinib, FOLFIRI, mFOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Unknown | Fudan University | 68 | 2022-12-01 | 2022-12-02 |
| Switch Maintenance in Pancreatic ZIMBERELIMAB, DOMVANALIMAB, APX005M - Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | Suspended | James Cleary, MD, PhD | 46 | 2022-11-30 | 2026-06-04 |
| Phase 2 Study of DKN-01 in Colorectal Cancer DKN-01, FOLFIRI, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Completed | Leap Therapeutics, Inc. | 188 | 2022-08-30 | 2025-08-03 |
| SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies SI-B001, Irinotecan, FOLFIRI Protocol - Colorectal Cancer | Phase 2 | Terminated | Sichuan Baili Pharmaceutical Co., Ltd. | 7 | 2021-11-30 | 2024-07-18 |
| Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 204 | 2021-11-15 | 2025-03-26 |
Showing 20 of 73. Sign in to see all of them.
Colorectal Neoplasms (52) · Colonic Neoplasms (11) · Neoplasm Metastasis (9) · Rectal Neoplasms (9) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Pancreatic Neoplasms (3) · Adenocarcinoma (2) · Brain Neoplasms (2) · Carcinoma, Neuroendocrine (2) · Stomach Neoplasms (2) · Astrocytoma (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1)
Amgen (4) · Cardiff Oncology (3) · Federation Francophone de Cancerologie Digestive (3) · Fudan University (3) · Eisai Inc. (2) · Genentech, Inc. (2) · Hoffmann-La Roche (2) · Ruijin Hospital (2) · 4SC AG (1) · AIO-Studien-gGmbH (1) · AbbVie (1) · Abramson Cancer Center at Penn Medicine (1) · Biotheus Inc. (1) · Bristol-Myers Squibb (1) · CR-CSSS Champlain-Charles-Le Moyne (1)
United States (23) · France (13) · China (12) · Italy (12) · Spain (12) · Germany (9) · Australia (6) · Canada (5) · South Korea (5) · United Kingdom (5) · Belgium (4) · Israel (4) · Singapore (4) · Argentina (3) · Austria (3)
Harish Dave (2) · Roberto Labianca, MD (2) · Alberto Zaniboni, MD (1) · Armando Santoro, MD (1) · Benoit Samson, MD (1) · Changping Wu, M.D. (1) · Cynthia Sirard (1)
PMID 22070868, PMID 39475591, PMID 22000810, PMID 22576338, PMID 23361051, PMID 23493136, PMID 23955585, PMID 24905030, PMID 30080723, PMID 30840064, PMID 31300973, PMID 31515083, PMID 32766143, PMID 32921581, PMID 34646387, PMID 35202974, PMID 35484400, PMID 36739879, PMID 36860319, PMID 37337155, PMID 37535388, PMID 38231047, PMID 38573643, PMID 40275077, PMID 40531517, PMID 41852303, PMID 42736431
2025 (4), 2008 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1)